CSBR
Get informed when a big investor buys or sells
+ FollowOvervalued by 98.3% based on the discounted cash flow analysis.
| Market cap | $73.64 Million |
|---|---|
| Enterprise Value | $99.24 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.08 |
| Beta | 0.4 |
| Outstanding Shares | 13,897,535 |
| P/E Ratio | -67.09 |
|---|---|
| PEG | 781.58 |
| Price to Sales | 1.67 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.25 |
| Enterprise Value to EBIT | -65.85 |
| Enterprise Value to Net Income | -88 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 7.7 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 42.58%▲ 1.13% |
|---|---|
| Total Invested | $36.28M▲ 10.06% |
| Investors Holding | 27▲ 2.00% |
No data
Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computa...